In its latest quarterly disclosures, SciSparc Ltd. highlighted a significant collaboration between its majority-owned subsidiary NeuroThera Labs and Clearmind Medicine, resulting in a new patent application targeting depression therapy. Additionally, NeuroThera is acquiring a controlling stake in CliniQuantum Ltd., broadening SciSparc’s exposure to quantum-driven clinical trial technologies. These strategic moves reinforce SciSparc’s position in the cannabinoid pharmaceutical space focused on neurological and neuropsychiatric disorders. However, liquidity constraints and operating losses remain key challenges as SciSparc advances multiple clinical-stage programs alongside its nutraceutical business.